Drug Name | Company | Therapy Area | Year |
Ravulizumab (ALXN-1210; Ultomiris) |
Alexion Pharmaceuticals Inc. | Excessive immune response/autoimmunity, Genetic disorder | 2019 |
Risankizumab (BI-655066; ABBV-066; Skyrizi) |
AbbVie Inc., Boehringer Ingelheim | Excessive immune response/autoimmunity | 2019 |
Roxadustat (FG-4592; AZD-9941; ASP-1517; Ai Rui Zhuo) |
Astellas Pharma Inc., AstraZeneca plc, FibroGen | Chronic disease complication | 2019 |
Upadacitinib (ABT-494; Rinvoq) |
AbbVie Inc. | Excessive immune response/autoimmunity | 2019 |
Apalutamide (Erleada) |
Johnson & Johnson | Oncology | 2018 |
Buprenorphine (Sublocade) |
Indivior plc | Addiction | 2018 |
Cannabidiol (Epidiolex) |
GW Pharmaceuticals plc | Neurology/psychiatric | 2018 |
Elagolix (Orilissa) |
AbbVie Inc. | Reproductive health | 2018 |
Emicizumab (Hemlibra) |
Chugai, Roche | Hematology | 2018 |
Erenumab (Aimovig) |
Amgen, Novartis International AG | Neurology/psychiatric | 2018 |
Ertugliflozin (Steglatro) |
Merck & Co., Pfizer Inc. | Endocrinology/metabolic disease | 2018 |
Lanadelumab (Takhzyro) |
Shire | Genetic disorder | 2018 |
Patisiran (Onpattro) |
Alnylam Pharmaceuticals Inc., Sanofi Genzyme | Genetic disorder | 2018 |
Shingrix vaccine |
GlaxoSmithKline plc | Infectious disease | 2018 |
Tenofovir alafenamide plus emtricitabine plus bictegravir (Biktarvy) |
Gilead Sciences Inc. | Infectious disease | 2018 |
Avelumab (Bavencio) |
Merck Serono, Pfizer Inc. | Oncology | 2017 |
Axicabtagene ciloleucel (KTE-C19; Yescarta) |
Kite Pharma | Oncology | 2017 |
Baricitinib (Olumiant) |
Eli Lilly and Co., Incyte Corp. | Excessive immune response/autoimmunity | 2017 |
Dupilumab (Dupixent) |
Regeneron Pharmaceuticals Inc., Sanofi SA | Excessive immune response/autoimmunity | 2017 |
Durvalumab (Imfinzi) |
AstraZeneca plc | Oncology | 2017 |
Niraparib (Zejula) |
Tesaro | Oncology | 2017 |
Ocrelizumab (Ocrevus) |
Roche | Neurology/psychiatric | 2017 |
Ribociclib (LEE-011; Kisqali) |
Novartis International AG | Oncology | 2017 |
Semaglutide (Ozempic) |
Novo Nordisk A/S | Endocrinology/metabolic disease | 2017 |
Emtricitabine plus tenofovir alafenamide (Descovy) |
Gilead Sciences Inc., Japan Tobacco | Infectious disease | 2016 |
Grazoprevir plus elbasvir (MK-5172A) |
Merck & Co. | Infectious disease | 2016 |
Obeticholic acid (Ocaliva) |
Intercept Pharmaceuticals, Sumitomo Dainippon Pharma | Hepatology | 2016 |
Pimavanserin (Nuplazid) |
ACADIA Pharmaceuticals | Neurology/psychiatric | 2016 |
Tenofovir alafenamide plus emtricitabine plus rilpivirine (Odefsey) |
Gilead Sciences Inc., Janssen R&D | Infectious disease | 2016 |
Selexipag (Uptravi) |
Actelion, Nippon Shinyaku Co. | Cardiovascular disease | 2016 |
Venetoclax (Venclexta; Venclyxto) |
AbbVie Inc. | Oncology | 2016 |
Alirocumab (Praluent) |
Regeneron Pharmaceuticals Inc., Sanofi SA | Cardiovascular disease | 2015 |
Brexpiprazole (Rexulti) |
Lundbeck, Otsuka Pharmaceutical | Neurology/psychiatric | 2015 |
Evolocumab (Repatha) |
Amgen, Astellas Pharma Inc. | Cardiovascular disease | 2015 |
Gardasil 9 vaccine |
Merck & Co. | Infectious disease | 2015 |
Insulin glargine (Toujeo) |
Sanofi SA | Endocrinology/metabolic disease | 2015 |
Lumacaftor plus ivacaftor (Orkambi) |
Vertex Pharmaceuticals Inc. | Respiratory disease | 2015 |
Nivolumab (Opdivo) |
Bristol-Myers Squibb Co. | Oncology | 2015 |
Palbociclib (Ibrance) |
Pfizer Inc. | Oncology | 2015 |
Sacubitril plus valsartan (LCZ-696) |
Novartis International AG | Cardiovascular disease | 2015 |
Secukinumab (Cosentyx) |
Novartis International AG | Excessive immune response/autoimmunity | 2015 |
Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak) |
AbbVie Inc. | Respiratory disease | 2015 |
Idelalisib (Zydelig) |
Gilead Sciences Inc. | Oncology | 2014 |
Sofosbuvir (Sovaldi) |
Gilead Sciences Inc. | Infectious disease | 2014 |
Vilanterol plus umeclidinium (Anoro Ellipta) |
GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2014 |
Apremilast (Otezla) |
Celgene Corporation | Excessive immune response/autoimmunity | 2013 |
Fluticasone furoate plus vilanterol trifenatate (Relovair) |
GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |
Icosapent ethyl ester (Vascepa) |
Amarin Corporation plc | Cardiovascular disease | 2013 |
Pomalidomide (Pomalyst) |
Celgene Corporation | Oncology | 2013 |
Trastuzumab emtansine (T-DM1) |
Roche | Oncology | 2013 |
影響2023年全球醫藥市場的主要因素包括:中國大陸對於生物製劑需求增加、生物相似性藥品興起、個人化藥物研發取得進展,以及聯合國永續發展目標中的重點疾病治療